A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1
200
about 2.5 years
18+
6 sites in CO, FL, MA +2
What this study is about
This trial is testing the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. It includes three parts: a dose escalation trial of STRO-004 monotherapy, a cohort expansion to further evaluate STRO-004 monotherapy, and a dose escalation of STRO-004 combined with pembrolizumab.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Pembrolizumab
- 2.Take STRO-004
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Part 1A, 1B: Percentage of participants with Treatment-Emergent Adverse Events (TEAEs), with severity determined according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale, Part 1B: Disease control rate (DCR), Part 1B: Duration of Response (DOR), Part 1B: Objective Response Rate (ORR), Part 1B: Progression-Free Survival (PFS), Part 1C: Percentage of participants with TEAEs, with severity determined according to the CTCAE v5.0 grading scale
Secondary: Part 1A, 1C: Disease Control Rate (DCR), Part 1A, 1C: Duration of Response (DOR), Part 1A,1C: Progression-Free Survival (PFS), Part 1A: Objective Response Rate (ORR)
Oncology